BOEHRINGER-INGELHEIM
2.6.2021 14:02:09 CEST | Business Wire | Press release
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078) today announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis (NASH). The Fast Track Designation facilitates the development and expedites the review of new therapies to treat serious conditions and fill an unmet medical need. BI 456906 is currently being evaluated in a Phase II study in adults with NASH and liver fibrosis (F2/F3) with and without diabetes.
“The FDA Fast Track Designation for our dual agonist is an important step forward in addressing the high unmet medical need among the up to 444 million adults estimated to be living with NASH,” said Waheed Jamal, MD, Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “Together with our partner Zealand Pharma, we look forward to working closely with the FDA as we explore the potential of the GLP-1/glucagon agonist to improve outcomes for adults with NASH.”
“Boehringer Ingelheim and Zealand Pharma are committed to delivering innovative solutions that address public health challenges of cardiometabolic diseases, including NASH,” said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. “By combining Boehringer Ingelheim’s expertise in drug development in the cardio-metabolic area with our strength in the discovery of innovative peptide-based medicines, we have the potential to bring forward a novel therapy option in an area with limited available treatments.”
The GLP-1/glucagon compound derived from the natural gut hormone oxyntomodulin activates both the GLP-1 and glucagon receptors that are critical to controlling metabolic functions. The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments. It is also being investigated as a potential treatment option for adults living with diabetes and for adults living with obesity. It is part of Boehringer Ingelheim’s research and development portfolio in the cardiometabolic disease areas.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/fast-track-designation-nash
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005582/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABS Acquires RMC Global to Strengthen Cyber, Risk and Resilience Capabilities30.4.2026 17:46:00 CEST | Press release
Acquisition to Deliver Stronger, More Integrated Solutions for Clients ABS, through its affiliate ABSG Consulting Inc. (ABS Consulting), has today announced the acquisition of RMC Global (RMC), a leading provider of industrial cybersecurity, risk management and resiliency solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430164690/en/ (L to R): Vince Kuchar, President, RMC Global, and David Wechsler, President and CEO, ABS Group The acquisition strengthens ABS Consulting’s capabilities and market position, bringing together two organizations with complementary expertise, shared values and a common mission. Combining RMC’s capabilities with ABS Consulting’s scale, technical depth and global resources, unlocks more integrated solutions for clients operating in increasingly complex risk environments. ABS Chairman and CEO John McDonald said: “Clients are facing increasing operational risk, cyber threats, and regulator
Brightfin Unveils AI-Native Platform for IT Financial Management30.4.2026 17:00:00 CEST | Press release
Brightfin clients drive their businesses forward with the first AI Native Cost Optimization Platform Brightfin, the only ITFM and Technology Expense Management solution built natively on ServiceNow, today announced an AI-Native architecture that fundamentally improves how organizations manage IT spend. Rather than bolting AI onto legacy systems, Brightfin has engineered intelligence from the ground up - starting with the data, building contextual awareness on top of it, and delivering AI agents that speak the language of IT finance. Brightfin’s unified budget-to-billing data model creates a stable, governed foundation that connects contracts, invoices, inventory, and budgets into a single source of truth - something no external ITFM tool or native platform module can replicate. This is a structured financial backbone purpose-built for enterprise IT spend, and it’s what makes everything above it possible. A context-aware, AI-Native, intelligence layer understands relationships across th
SINOVAC Files Annual Report on Form 20-F for the Fiscal Year 202430.4.2026 15:22:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Annual Report”) with the U.S. Securities and Exchange Commission (“SEC”). An electronic copy of the Annual Report can be accessed on SINOVAC’s investor relations website at https://www.sinovac.com/en-us/Investors and on the SEC’s website at www.sec.gov. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of “supply vaccines to eliminate human diseases”, the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases. The company’s diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, et
Experian Announces Agent Trust to Power Trusted AI Driven Commerce30.4.2026 15:00:00 CEST | Press release
First-of-its-kind human-to-agent binding service for secure AI-driven commerce, developed with a growing ecosystem of agentic commerce collaborators, including Visa, Cloudflare and Skyfire Experian today announced Experian Agent Trust™, a first-of-its-kind framework that establishes a secure, verifiable link between consumers and AI agents, bringing identity, and accountability to AI-driven transactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430719198/en/ Experian Announces Agent Trust to Power Trusted AI Driven Commerce. As AI agents begin to search and transact autonomously, they introduce a fundamental challenge for businesses: how to trust an action when it is no longer driven by a human. Without a verified connection between humans and AI agents, autonomous commerce introduces new risks in fraud, misrepresentation, and unauthorized transactions. Experian Agent Trust addresses this challenge through a new “Kn
Meet the AI-powered fan companion: TGR Haas F1 Team RaceMate powered by Infobip30.4.2026 15:00:00 CEST | Press release
New always-on conversational agent with team race intelligence, team insights, and interactive experiences powered by Infobip AgentOS Global AI-first cloud communications platform Infobip and TGR Haas F1 team are launching ‘TGR Haas F1 Team RaceMate powered by Infobip’, an AI-powered conversational fan companion on Apple Messages for Business and WhatsApp Business Platform. Always-on and always available, it delivers race intelligence for TGR Haas F1 Team: team race intelligence, grid positions, qualifying outcomes, sprint results, and full session schedules. The AI agent tracks drivers Ollie Bearman and Esteban Ocon with their individual championship standings and performance data in conversational format. The agent draws from a knowledge base covering driver biographies, team history, and circuit data, adapting to each user's knowledge level. Every interaction begins with a schedule check, ensuring fans always know what's happening right now. It proactively surfaces relevant informat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom